Affinity peptide for resisting IHN virus and application thereof

By developing polypeptides that specifically bind to rainbow trout SOCS-1 and modifying amino-terminal, carboxy-terminal protecting groups and fatty acids, the SWWFPQWMAQYP polypeptide was prepared, which solved the problem of IHN virus being difficult to inhibit in rainbow trout breeding and achieved the virus Effective inhibition and prevention.

CN119019506AActive Publication Date: 2024-11-26NORTHEAST AGRICULTURAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411144353.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit and prevent infectious hematopoietic organ necrosis caused by IHN virus, especially in rainbow trout breeding, which lacks effective prevention and control methods and faces the dual threat of domestic and foreign strains.

Method used

A polypeptide or a pharmaceutically acceptable salt or derivative thereof was developed, and the effect of anti-IHN viruses was enhanced by specifically binding to rainbow trout SOCS-1 and modified with amino-terminal, carboxy-terminal protecting groups and fatty acids. SWWFPQWMAQYP polypeptide, used to inhibit the reproduction of viruses.

Benefits of technology

The use of SWWFPQWMAQYP polypeptide significantly reduced the titer and gene expression of the IHN virus, demonstrating its effectiveness in inhibiting viral reproduction and preventing disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019506A_ABST
    Figure CN119019506A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-IHN virus affinity peptide and application thereof, and aims to solve the technical problem of how to inhibit IHN virus reproduction. Specifically disclosed is a polypeptide or a pharmaceutically acceptable salt thereof or a derivative thereof, the polypeptide having the formula (I): SWWFPQWMAQYP-X1-X2 (I) wherein X1 represents GGS or is absent, and X1 represents YPYDVPDYA or is absent. According to the present invention, after the SWWFPQWMAQYPGGSYPYDVPDYA polypeptide is chemically synthesized, the YPYDVPDYA is adopted as the contrast, the RTG-2 cell is treated, the IHN virus is inoculated, and the titer of the IHN virus treated by the SWWFPQWMAQYPGGSYPYDVPDYA is significantly lower than the titer of the YPYDVPDYA; therefore, the SWWFPQWMAQYP polypeptide can be used for inhibiting the reproduction of the IHN virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application specifically relates to affinity peptides against IHN virus and their applications. Background Art

[0002] Rainbow trout (Oncorhynchus mykiss) belongs to the salmonid family and is a cold-water fish that is mainly farmed and consumed in my country. However, the increasingly prominent disease situation has restricted the sustainable development of my country's rainbow trout industry. Among them, the disease caused by infectious hematopoietic necrosis virus (IHNV) infection has become one of the most difficult rainbow trout disease problems due to its long incubation period, explosive death and high mortality rate.

[0003] Due to the lack of specific drugs for preventing and treating IHNV infection, my country's rainbow trout aquaculture industry is facing the dual threats of domestic strain prevalence and mutation, as well as foreign strain importation. Therefore, how to provide an effective means to resist IHNV is a problem faced by those skilled in the art. Summary of the invention

[0004] The technical problem solved by the present invention is how to inhibit the reproduction of IHN virus and / or prevent or treat or assist in treating diseases caused by IHN virus, especially infectious hematopoietic necrosis.

[0005] In order to solve the above problems, the present application provides a polypeptide or a pharmaceutically acceptable salt or a derivative thereof.

[0006] The amino acid sequence of the polypeptide is sequence 1, sequence 3, sequence 2 or sequence 4 in the sequence list.

[0007] In order to solve the above problems, the present application also provides a polypeptide derivative, wherein the derivative is a compound obtained by subjecting the above polypeptide to at least one of the following modifications:

[0008] A1) a compound obtained by connecting an amino terminal protecting group to the amino terminal of the polypeptide and / or connecting a carboxyl terminal protecting group to the carboxyl terminal of the polypeptide;

[0009] A2) a polypeptide capable of specifically binding to rainbow trout SOCS-1 and resisting IHN virus obtained by adding amino acid residues to the amino terminus and / or carboxyl terminus of the polypeptide;

[0010] A3) A polypeptide capable of specifically binding to rainbow trout SOCS-1 and resisting IHN virus is obtained by connecting fatty acids to the amino terminus and / or carboxyl terminus of the polypeptide.

[0011] The amino acid sequence of rainbow trout SOCS-1 is sequence 6, which is as follows:

[0012] MVAHSAVEEQDTTTKPPSSSPSRPLGASSTFLSTPHSDHHTTSPSSSSPPSSSSSVSQSHRPRPSNQCVASPIPGPDLLDHQPPLPLLDPVPTHFPLFPCKVDFLLITRTAAMLERSGFYWGPLGV EEAHTRLKDVATGTFLIRDSRQTDVFFTLSYRAASGPVSVRIVYKGQRFSLAGSEHSFPCLFLLLLEHYINSSKKSLTVPYRKQRPTLQELCRKQVAESCGGEVERVARVPVNPVLKHFLLEFPYRI.

[0013] In the present invention, the amino terminal protecting group or the carboxyl terminal protecting group may be any one of acetyl, amino, maleyl, succinyl, tert-butyloxycarbonyl or benzyloxy or other hydrophobic groups or macromolecular carrier groups; the carboxyl terminal of the cyclic polypeptide of the present invention may contain a carboxyl terminal protecting group, and the carboxyl terminal protecting group may be any one of amino, amide, carboxyl, or tert-butyloxycarbonyl or other hydrophobic groups or macromolecular carrier groups.

[0014] In order to solve the above problems, the present application also provides compounds.

[0015] The derivative is a compound of formula (I): F1-K-SWWFPQWMAQYP-X1-X2-F2 (Formula I), wherein F1 is a fatty acid, K is a group connecting F1 and SWWFPQWMAQYP, X1 represents GGS or does not exist, X2 represents YPYDVPDYA or does not exist, and F2 is a carboxyl terminal protecting group.

[0016] In the above compounds, K, S, W, F, Q, M, A, Y, G, D, V and P represent different amino acids.

[0017] In the above compounds, K may be an amino acid.

[0018] In the above compounds, K may be lysine.

[0019] In the above compounds, different amino acids may be linked by peptide bonds.

[0020] In the above compounds, the carboxyl terminal protecting group is an amino group.

[0021] In the above-mentioned compound, the fatty acid may be palmitic acid.

[0022] In the above text, the palmitic acid molecular formula is C 16 H 32 O2.

[0023] In the above, the carboxyl terminal protecting group may be amidation-modified.

[0024] In the above, the F1 can be palmitic acid, and K can be an amino acid. The palmitic acid carboxyl group and the N-terminal amino group of lysine are dehydrated and condensed.

[0025] In the above, the F2 may be an amino group. The C-terminal amino group of the derivative is modified.

[0026] In the above, the other letters in (Formula I), the capital letters in X1 and X2 are all amino acids. Amino acids have well-known meanings in the art, for example: C is cysteine, D is aspartic acid, E is glutamic acid, Y is tyrosine, F is phenylalanine, W is tryptophan, V is valine, H is histidine, etc. All amino acids in the cyclic polypeptide sequence can be L-type amino acids, and one or more (such as 2-5, 2-4 or 2-3) of the amino acids can also be replaced with amino acids with D-type conformation, artificially modified amino acids, rare amino acids existing in nature, etc., to improve the bioavailability, stability and / or antiviral activity of the cyclic polypeptide. Among them, D-type amino acids refer to amino acids corresponding to L-type amino acids that constitute proteins; artificially modified amino acids refer to common L-type amino acids that constitute proteins that have been modified by methylation, phosphorylation, etc.; rare amino acids existing in nature include uncommon amino acids that constitute proteins and amino acids that do not constitute proteins, such as 5-hydroxylysine, methylhistidine, γ-aminobutyric acid, homoserine, etc.

[0027] In the present application, the carboxyl terminal protecting group is an amino group, and the amino group is modified by amidation of the carboxyl terminal.

[0028] The fatty acid may be F1, F2 or F3:

[0029] F1, saturated fatty acids or unsaturated fatty acids;

[0030] F2, saturated fatty acids containing 8 to 20 carbon atoms;

[0031] F3, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid or arachidic acid.

[0032] In the above polypeptide, the protein tag refers to a polypeptide or protein fused and expressed with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.

[0033] In the above polypeptides, identity refers to the identity of the amino acid sequence. The identity of the amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST page on the NCBI homepage website. For example, in Advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting the Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively, and searching for the identity of a pair of amino acid sequences, the identity value (%) can be obtained.

[0034] In the above polypeptides, the above 80% identity may be at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 95%, 96%, 98%, 99% or 100% identity.

[0035] One or more amino acids of the polypeptide of the present invention can be replaced with amino acids with D-type conformation, artificially modified amino acids, rare amino acids existing in nature, etc., to improve the bioavailability, stability and / or anti-cancer activity of the polypeptide. Among them, D-type amino acids refer to amino acids corresponding to L-type amino acids constituting proteins; artificially modified amino acids refer to common L-type amino acids constituting proteins that have been modified by methylation, phosphorylation, etc.; rare amino acids existing in nature include uncommon amino acids constituting proteins and amino acids that do not constitute proteins, such as 5-hydroxylysine, methylhistidine, γ-aminobutyric acid, homoserine, etc.

[0036] Use of the above polypeptide or its pharmaceutically acceptable salt or the above polypeptide derivative or any of the above compounds in the preparation of drugs for preventing and / or treating and / or assisting in the treatment of infectious hematopoietic necrosis.

[0037] Use of the above polypeptide or its pharmaceutically acceptable salt or the above polypeptide derivative or any of the above compounds in the preparation of drugs for preventing and / or treating and / or assisting in the treatment of diseases caused by infectious hematopoietic necrosis virus.

[0038] Use of the above polypeptide or its pharmaceutically acceptable salt or the above polypeptide derivative or any of the above compounds in the preparation of anti-IHN virus drugs.

[0039] In order to solve the above problems, the present application also provides an anti-IHN virus drug.

[0040] The drug comprises the above polypeptide or a pharmaceutically acceptable salt thereof or a derivative of the above polypeptide or the above compound. Summary of the invention:

[0042] In the above, the drug also includes a pharmaceutically acceptable carrier or excipient.

[0043] Carriers or excipients include, but are not limited to, water-soluble carrier materials (such as polyethylene glycol, polyvinyl pyrrolidone, organic acids, etc.), poorly soluble carrier materials (such as ethyl cellulose, cholesterol stearate, etc.), enteric carrier materials (such as cellulose acetate phthalate and carboxymethyl ethyl cellulose, etc.). Among them, water-soluble carrier materials are preferred. These materials can be made into a variety of dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections, etc. It can be a common preparation, a sustained-release preparation, a controlled-release preparation, and various microparticle delivery systems. In order to make a unit dosage form into a tablet, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch paste, dextrin, syrup, honey, glucose solution, acacia paste, gelatin paste, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinyl pyrrolidone, etc.; disintegrants. , such as dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid esters, sodium lauryl sulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, hydrogenated oil, etc.; absorption promoters, such as quaternary ammonium salts, sodium lauryl sulfate, etc.; lubricants, such as talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, etc. The tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets. In order to make the unit dosage form into a pill, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc.; binders such as gum arabic, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrants such as agar powder, dry starch, alginate, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc. In order to prepare the unit dosage form into a suppository, various carriers known in the art can be widely used. Examples of carriers include, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc. In order to prepare the unit dosage form into an injectable preparation, such as a solution, emulsion, freeze-dried powder injection and suspension, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc.In addition, in order to prepare isotonic injections, an appropriate amount of sodium chloride, glucose or glycerol may be added to the injection preparation. In addition, conventional cosolvents, buffers, pH adjusters, etc. may also be added. In addition, if necessary, colorants, preservatives, spices, flavoring agents, sweeteners or other materials may also be added to the pharmaceutical preparation. The above dosage forms can be administered by injection, including subcutaneous injection, intravenous injection, intramuscular injection and intracavitary injection, etc.; cavity administration, such as rectal and vaginal administration; respiratory administration.

[0044] In order to solve the above problems, the present application also provides a method for preparing an anti-IHN virus drug.

[0045] The method comprises using the above polypeptide or its pharmaceutically acceptable salt or the above polypeptide derivative or any of the above compounds as a drug component to obtain an anti-IHN virus drug.

[0046] In the present application, the IHN virus may be infectious hematopoietic necrosis virus.

[0047] In the present application, the Latin name of the infectious hematopoietic necrosis virus is Infectioushematopoietic necrosis virus.

[0048] Beneficial Effects

[0049] The present invention firstly utilizes phage display peptide library panning technology to screen and obtain a polypeptide sequence capable of binding to rainbow trout SOCS-1, and chemically synthesizes and modifies the rainbow trout SOCS-1 affinity peptide accordingly, and chemically synthesizes the SWWFPQWMAQYPGGSYPYDVPDYA polypeptide, wherein YPYDVPDYA is an HA tag and GGS is a connecting peptide; the N-terminus is modified with fatty acids to enhance the cell permeability of the affinity peptide; the C-terminus is introduced with an HA tag and amidation modification to facilitate subsequent detection and ensure the stability of the affinity peptide; with an HA control peptide (YPYDVPDYA) as a control, the SWWFPQWMAQYPGGSYPYDVPDYA polypeptide is used to pre-treat RTG-2 cells, and then the IHN virus is inoculated; the titer of the IHN virus after being treated with the SWWFPQWMAQYPGGSYPYDVPDYA is significantly lower than that of the YPYDVPDYA, and it can be seen that the SWWFPQWMAQYP polypeptide can be used to inhibit the reproduction of the IHN virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 The relationship between SOCS-1 and IHNV infection.

[0051] Figure 2The diagrams show the gene cloning, recombinant protein expression and purification of SOCS-1; A shows the cloning of SOCS-1 gene, M: Trans2K DNA marker, 1: PCR product of SOCS-1 gene; B shows the prokaryotic expression of recombinant SOCS-1, M: Protein marker, 1: product after empty vector induction; 2: supernatant after ultrasonic lysis of SOCS-1 induced expression product; 3: precipitate after ultrasonic lysis of SOCS-1 induced expression product; C shows the purification and renaturation of recombinant SOCS-1 protein, M: Protein marker, 1: final product of recombinant SOCS-1 protein.

[0052] Figure 3 This is a diagram of the screening and identification of positive phages.

[0053] Figure 4 This is a validation diagram of the binding of SW affinity peptide to SOCS-1.

[0054] Figure 5 This is a graph showing the inhibitory effect of C16-SW affinity lipopeptide on IHNV.

[0055] Figure 6 The graph shows the inhibitory effect of SW-encoding plasmid on IHNV after cells were transfected. DETAILED DESCRIPTION

[0056] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0057] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0058] The following examples were processed using SPSS11.5 statistical software, and the experimental results were expressed as mean ± standard deviation. One-way ANOVA test was used, and P < 0.05 (*) indicated a significant difference, P < 0.01 (**) indicated a very significant difference, and P < 0.001 (***) indicated an extremely significant difference.

[0059] Example 1I Analysis of SOCS-1 Function during HNV Infection

[0060] Rainbow trout RTG-2 cells were infected with infectious hematopoietic necrosis virus (IHNV) at two challenge doses of 100 MOI and 10 MOI, or RTG-2 cells were treated with recombinant rainbow trout interferon, total RNA was extracted, and the expression level of SOCS-1 was detected by real time PCR. It was found that IHNV infection could cause a significant upregulation of SOCS-1 expression and the expression of this molecule increased accordingly with the replication of the virus ( Figure 1 The expression of interferon effector protein Mx1 was negatively correlated with SOCS-1 ( Figure 1 This indicates that IHNV infection can regulate SOCS-1 expression, and SOCS-1 expression may be related to the body's antiviral interferon response.

[0061] Example 2 Screening and identification of rainbow trout SOCS-1 affinity peptides

[0062] 2.1 Amplification of target gene and construction of recombinant prokaryotic expression plasmid

[0063] Using the rainbow trout SOCS-1 nucleotide sequence published in Genbank as a reference, a pair of primers for SOCS-1 amplification (5'- GGA TCC ATGGTCGCTCACAGTGCTGTG-3' and 5'- AAGCTT TTATATCCTGTACGGGAACTCT-3', the restriction endonuclease site is underlined, the upstream is BamHI, the downstream is HindIII), the RTG-2 cells (rainbow trout gonad cell line) were stimulated with the previously prepared recombinant rainbow trout interferon riIFN1a, RNA was extracted, reverse transcribed, and cDNA was obtained. PCR reaction was performed using SOCS-1 amplification primers as primers and cDNA as template, and finally a fragment of 774 bp was obtained ( Figure 2 A). The amplified product was digested and ligated with the prokaryotic expression vector pET-32a(+), and the ligated system was introduced into Escherichia coli Rosetta(DE3) TM After culturing the competent cells, a single colony was picked for sequencing, and the vector with correct sequencing was named the recombinant vector pET-32a(+)-SOCS-1.

[0064] The recombinant vector pET-32a(+)-SOCS-1 is a recombinant vector obtained by replacing the fragment between the restriction endonuclease BamHI and HindIII recognition sites in the prokaryotic expression vector pET-32a(+) with sequence 5, while keeping the other sites of the prokaryotic expression vector pET-32a(+) unchanged. The recombinant vector pET-32a(+)-SOCS-1 was transformed into Escherichia coli Rosetta (DE3) TM Escherichia coli Rosetta (DE3) was obtained from competent cells TM / recombinant vector pET-32a(+)-SOCS-1 (also known as Escherichia coli / recombinant vector pET-32a(+)-SOCS-1).

[0065] Sequence 5 is as follows:

[0066] Atggtcgctcacagtgctgtggaagaacaagacacaacaacaaaaccaccatcgtcgtcaccttctagacctctaggcgcctcctccaccttcctctcgactccacactcggaccaccacacaacctcaccatcatcatcatcaccaccatcgtcatcatcatcatcagtctcccagtcacaccgtccgcgcccatccaaccagtgtgtggcgtcccctatcccaggaccagacctgttagaccaccagccccctcttcccctcctggacccagtgcccacccactttcctctgttcccctgcaaggtagacttcctgttgatcactcggacggccgccatgttggaacgttccggcttctactggggcccgctaggagtggaggaggctcacactcgactgaaggacgttgccacgggaacattcttgatccgggacagtcgtcagacagacgtcttcttcacgctgtcctatcgcgcggccagcggcccggtcagcgtacgcatcgtctataagggacaacggttcagcctggcaggaagtgagcactctttcccctgcctcttcctcctgctcgaacactacataaattcctctaagaaaagcctgaccgttccgtacaggaagcagcgccctacgctccaggaactgtgcaggaaacaggtcgcggagtcgtgtggcggtgaggtggaacgggtcgccagggtccccgtcaacccagtcctaaaacacttcctgttagagttcccgtacaggatatga。

[0067] The amino acid sequence of rainbow trout SOCS-1 is Sequence 6, as follows:

[0068] MVAHSAVEEQDTTTKPPSSSPSRPLGASSTFLSTPHSDHHTTSPSSSSPPSSSSSVSQSHRPRPSNQCVASPIPGPDLLDHQPPLPLLDPVPTHFPLFPCKVDFLLITRTAAMLERSGFYWGPLGV EEAHTRLKDVATGTFLIRDSRQTDVFFTLSYRAASGPVSVRIVYKGQRFSLAGSEHSFPCLFLLLLEHYINSSKKSLTVPYRKQRPTLQELCRKQVAESCGGEVERVARVPVNPVLKHFLLEFPYRI.

[0069] 2.2 Prokaryotic expression and purification of recombinant proteins

[0070] The E. coli / recombinant vector pET-32a(+)-SOCS-1 was induced to express with 1.0 mM IPTG, and the recombinant SOCS-1 protein was obtained with a size of about 46 kDa ( Figure 2 Middle B). Recombinant SOCS-1 protein was purified by Ni-NTA affinity chromatography system ( Figure 2 After dialyzation and concentration determination, the cells were frozen and stored at -80°C.

[0071] 2.3 Screening of positive phages

[0072] Refer to Ph.D.-12 TM The operation manual of the phage display 12-peptide library kit v2 (NEB product, #E8210S) is summarized as follows: a. Coat the recombinant SOCS-1 protein diluted with carbonate buffer on the ELISA plate, block overnight, wash and add the diluted phage library (reagent in the #E8210S kit) for incubation. After sufficient washing, add the eluent and shake, transfer the supernatant to a 1.5mL centrifuge tube, and add the neutralizing solution.

[0073] b. Preparation of medium A: Add 10 g tryptone, 5 g yeast extract, and 5 g NaCl per 1 L of double distilled water, sterilize at 121°C for 30 min, and then cool to room temperature to obtain medium A.

[0074] Preparation of host strain culture: The phage host strain ER2738 was streaked (the phage host strain ER2738 is a component of the phage library in the commercial kit; Ph.D.-12 TM Phage Display 12 Peptide Library Kit v2 (NEB product, #E8210S) was used to culture a single colony in 20 ml of medium A, and shaken at 37°C, 200 rpm for 4-8 h until the early logarithmic growth period (OD600nm is 0.01-0.05) to obtain a host strain culture.

[0075] Add neutralized phage to the culture of phage host strain ER2738, shake at 37°C for 5h, centrifuge to obtain supernatant, add PEG-NaCl to precipitate at 4°C overnight, centrifuge to discard supernatant, add appropriate volume of TBS to resuspend precipitate, and perform titer determination. c. Mix the phage eluate diluted in multiple ratios with ER2738, add the mixture to the melted upper agar, pour onto the bottom agar, count the number of plaques formed, and calculate the phage titer.

[0076] According to the above steps, 5 rounds of panning were performed.

[0077] 2.4 Identification of positive phages

[0078] a. Coat the recombinant SOCS-1 protein diluted in carbonate buffer on an ELISA plate, use the phage amplification solution obtained by panning as the primary antibody, and use the HRP-labeled M13 antibody as the secondary antibody to screen positive phages.

[0079] b. Refer to the method in the third edition of the "Molecular Cloning Experiment Guide" to extract the phage genome, design primers for the empty vector M13KE, perform PCR reaction, identify positive phages by analyzing whether there is gene insertion, and send the extracted phage double-stranded DNA to a sequencing company for sequencing, and finally obtain the polypeptide sequence information displayed by the phage with higher affinity.

[0080] The sequence of the affinity peptide (SW affinity peptide) finally obtained is: SWWFPQWMAQYP (SEQ ID No. 1).

[0081] c. Coat the recombinant SOCS-1 protein on the ELISA plate and add 10 12 and 10 10 The positive phages displaying SW affinity peptide were added with HRP-labeled M13 antibody for color development and the OD was read. 450nm The results showed that the phage displaying SW affinity peptide had a 12 The amount of can bind to the target molecule SOCS-1, but not to the non-target molecule BSA ( Figure 3 ).

[0082] 3. Anti-IHN virus effect of rainbow trout SOCS-1 affinity peptide

[0083] 3.1 Preparation and identification of affinity peptides

[0084] Nanjing Jiepeptide Biotechnology Co., Ltd. was commissioned to chemically synthesize C16-SW affinity lipopeptide and C16-HA lipopeptide. The N-terminus of C16-SW affinity lipopeptide was modified with fatty acids (a lysine was introduced into the N-terminus of the SW affinity peptide, and palmitic acid was covalently bound to the lysine residue to form a fatty acid-modified polypeptide, i.e., lipopeptide) to enhance the cell penetration of the affinity peptide, and an HA tag was introduced into the C-terminus (to facilitate subsequent detection, the amino acid sequence of the HA tag is YPYDVPDYA), and amidation modification was performed (to enhance the stability of the affinity peptide) to obtain C16-SW affinity lipopeptide. The structural formula of C16-SW affinity lipopeptide is:

[0085] C 16 -K-SWWFPQWMAQYPGGSYPYDVPDYA-NH2, where C 16 is palmitic acid, K is lysine, and the amino acid sequence of the HA tag is YPYDVPDYA; GGS is a connecting peptide; NH2 (amino) is a carboxyl terminal protecting group - amino, that is, the carboxyl terminal is amidated; the lysine connecting modification group (C 16 ) and the amino acid (SWWFPQWMAQYPGGSYPYDVPDYA) of the polypeptide, the palmitic acid carboxyl group and the amino group (NH2) at the N-terminus of lysine are dehydrated and condensed to connect, and the lysine is peptide-bonded to the above polypeptide ((SWWFPQWMAQYPGGSYPYDVPDYA)); the C 16 (Palmitic acid) molecular formula is C 16 H 32 O2, CAS number is 57-10-3, other capital letters are amino acids.

[0086] A control lipopeptide was synthesized: C 16 -K-GGSYPYDVPDYA-NH2, where C 16 is palmitic acid, K is lysine, and the amino acid sequence of the HA tag is YPYDVPDYA; GGS is a connecting peptide; NH2 (amino) is a carboxyl terminal protecting group - amino, that is, the carboxyl terminal is amidated; the lysine connecting modification group (C 16 ) and the amino acid (GGSYPYDVPDYA) of the polypeptide, the palmitic acid carboxyl group and the amino group (NH2) at the N-terminus of lysine are dehydrated and condensed, and the lysine is peptide-bonded to the above polypeptide ((GGSYPYDVPDYA)); the C 16 (Palmitic acid) molecular formula is C 16 H 32 O2, CAS number is 57-10-3, other capital letters are amino acids.

[0087] Sequence 1 is as follows: SWWFPQWMAQYP.

[0088] Sequence 2 is as follows: SWWFPQWMAQYPGGSYPYDVPDYA.

[0089] Sequence 3 is as follows: KSWWFPQWMAQYP.

[0090] Sequence 4 is as follows: KSWWFPQWMAQYPGGSYPYDVPDYA.

[0091] The pcDNA3.1-Flag-SOCS1 recombinant plasmid was constructed and transiently transfected into RTG-2 cells. After 24 hours, the cells were treated with WB&IP cell lysate, and immunoprecipitation was performed using anti-Flag agarose. The final eluate (i.e., eukaryotic SOCS-1 protein) was collected. The prokaryotic recombinant SOCS-1 protein and the eukaryotic SOCS-1 protein were coated on an ELISA plate, and then the synthetic affinity peptide was added. After incubation, HA antibody was added, color was developed, and the value was read. The final results showed that C16-SW affinity lipopeptide can bind to SOCS-1 outside the cell ( Figure 4 (A).

[0092] The pcDNA3.1-Flag-SOCS1 recombinant plasmid was transiently transfected into RTG-2 cells, and then the cells were incubated with 20, 6.7, and 2.3 μM C16-SW affinity lipopeptides. After 24 hours, the cells were collected and lysed, and immunoprecipitated with anti-Flag agarose, and the final eluate was collected. The eluate was directly coated on the ELISA plate, and then Flag or HA antibodies were added. The values ​​were read after color development. The detection results of Flag antibodies showed that after pcDNA3.1-Flag-SOCS1 was transfected into cells, anti-Flag antibodies could be used for immunoprecipitation. The detection results of HA antibodies showed that the synthesized C16-SW affinity lipopeptide could penetrate into the cells and bind to SOCS-1. The ELISA plate was coated with prokaryotically expressed SOCS-1 protein, then incubated with the eluent, and then HA antibody was added. The values ​​were read after color development. The results showed that the affinity peptide that co-precipitated with SOCS-1 in the cell could be competitively bound by recombinant prokaryotically expressed SOCS-1, further confirming that the affinity peptide can bind to SOCS-1 both inside and outside the cell ( Figure 4 (B).

[0093] 3.2 Antiviral effect of affinity peptides

[0094] Nanjing Jiepeptide Biotechnology Co., Ltd. was commissioned to chemically synthesize C16-SW affinity lipopeptide and C16-HA lipopeptide. The N-terminus of C16-SW affinity lipopeptide was modified with fatty acids to enhance the cell penetration of the affinity peptide, and the C-terminus was introduced with an HA tag (for subsequent detection), and amidation modification was performed (to enhance the stability of the affinity peptide) to obtain C16-SW affinity lipopeptide. The structural formula of C16-SW affinity lipopeptide is:

[0095] C 16 -K-SWWFPQWMAQYPGGSYPYDVPDYA-NH2, where C 16 is palmitic acid, K is lysine, and the amino acid sequence of the HA tag is YPYDVPDYA; GGS is a connecting peptide; NH2 (amino) is a carboxyl terminal protecting group - amino, that is, the carboxyl terminal is amidated; the lysine connecting modification group (C 16 ) and the amino acid (SWWFPQWMAQYPGGSYPYDVPDYA) of the polypeptide, the palmitic acid carboxyl group and the amino group (NH2) at the N-terminus of lysine are dehydrated and condensed to connect, and the lysine is peptide-bonded to the above polypeptide ((SWWFPQWMAQYPGGSYPYDVPDYA)); the C 16 (Palmitic acid) molecular formula is C 16 H 32 O2, CAS number is 57-10-3, other capital letters are amino acids.

[0096] A control lipopeptide was synthesized: C 16 -K-GGSYPYDVPDYA-NH2, where C 16 is palmitic acid, K is lysine, and the amino acid sequence of the HA tag is YPYDVPDYA; GGS is a connecting peptide; NH2 (amino) is a carboxyl terminal protecting group - amino, that is, the carboxyl terminal is amidated; the lysine connecting modification group (C 16 ) and the amino acid (GGSYPYDVPDYA) of the polypeptide, the palmitic acid carboxyl group and the amino group (NH2) at the N-terminus of lysine are dehydrated and condensed, and the lysine is peptide-bonded to the above polypeptide ((GGSYPYDVPDYA)); the C 16 (Palmitic acid) molecular formula is C 16 H 32 O2, CAS number is 57-10-3, other capital letters are amino acids.

[0097] Preparation of IHN virus solution (Infectious hematopoietic necrosis virus, Latin name Infectious hematopoietic necrosis virus, abbreviated as IHNV): One day before virus inoculation, EPC cells (source ATCC, catalog number CRL-2872) were subcultured in a T25 cell culture flask. The cell confluence on the day of inoculation was expected to be 80-90%. The IHN virus (IHN virus is a clinical isolate, recorded in the following literature: "Host miR-146a-3pFacilitates Replication of Infectious Hematopoietic Necrosis Virus byTargeting WNT3a and CCND1", which is called IHNV in this document), was diluted 1:1000 with M199 medium, and then adsorbed to cells for 2 hours. Then, fresh M199 medium containing 4% fetal bovine serum was replaced and cultured at 15°C until obvious cytopathic effects occurred (about 5-7 days). The cell culture containing the virus was repeatedly frozen and thawed three times, and the supernatant was collected after centrifugation at 1000 rpm to obtain the IHN virus solution. The obtained virus solution was analyzed by TCID using the Reed-Muench method. 50 The virus solution was then stored in a -80°C refrigerator.

[0098] 50TCID 50 Preparation of IHN virus solution: Dilute the above-prepared IHN virus solution with Eagle's Minimum Essential Medium (ATCC, Catalog No. 30-2003) to 2×10 5.53 times to obtain 50TCID 50 IHN virus fluid.

[0099] Preparation of 20 mg / mL C16-SW affinity lipopeptide: Dissolve the C16-SW affinity lipopeptide (4 mg) chemically synthesized by Nanjing Jiepeptide Biotechnology Co., Ltd. in 0.2 mL of DMSO, dilute the concentration of C16-SW affinity lipopeptide to 20 mg / mL, and obtain 20 mg / mL C16-SW affinity lipopeptide mother solution (also called C16-SW affinity lipopeptide mother solution).

[0100] 5 μg / mL C16-SW affinity lipopeptide dilution: 20 mg / mL of C16-SW affinity lipopeptide stock solution (also known as C16-SW affinity lipopeptide mother solution) was diluted to a final concentration of 5 μg / mL of C16-SW affinity lipopeptide using medium B containing 0.2% (V:V) DMSO to obtain a 5 μg / mL C16-SW affinity lipopeptide dilution.

[0101] 10 μg / mL C16-SW affinity lipopeptide dilution: 20 mg / mL of C16-SW affinity lipopeptide stock solution (also known as C16-SW affinity lipopeptide mother solution) was diluted to a final C16-SW affinity lipopeptide concentration of 10 μg / mL using medium B containing 0.2% (V:V) DMSO to obtain a 10 μg / mL C16-SW affinity lipopeptide dilution.

[0102] 20 μg / mL C16-SW affinity lipopeptide dilution; 20 mg / mL C16-SW affinity lipopeptide stock solution (also known as C16-SW affinity lipopeptide mother solution) is diluted with B culture medium containing 0.2% (V:V) DMSO to a final concentration of C16-SW affinity lipopeptide of 20 μg / mL to obtain 20 μg / mL C16-SW affinity lipopeptide dilution.

[0103] HA control lipopeptide stock solution: The control lipopeptide (4 mg) chemically synthesized by Nanjing Jiepeptide Biotechnology Co., Ltd. was dissolved in 0.2 mL of DMSO, and the concentration of the HA control lipopeptide was diluted to 20 mg / mL to obtain the HA control lipopeptide stock solution.

[0104] RTG-2 cells are rainbow trout gonadal cell lines (RTG-2): purchased from ATCC, with the catalog number CCL-55.

[0105] Preparation of B culture medium: Add 10% fetal bovine serum (Wisent, catalog number 086-150) and 1% penicillin-streptomycin double antibody solution (HyClone, catalog number SV30010) to Eagle's Minimum Essential Medium (ATCC, catalog number 30-2003) to obtain B culture medium.

[0106] Preparation of C culture medium: 4% fetal bovine serum (Wisent, catalog number 086-150) and 1% penicillin-streptomycin double antibody solution (HyClone, catalog number SV30010) were added to Eagle's Minimum Essential Medium (ATCC, catalog number 30-2003) to obtain C culture medium.

[0107] RTG-2 cell culture medium: RTG-2 cells were inoculated into medium B, cultured at 20°C and 5% CO2 until a monolayer was confluent, to obtain RTG-2 cell culture medium, and the culture was repeated multiple times in parallel.

[0108] Antiviral detection experiment of affinity peptide:

[0109] The experiment was divided into 6 groups, namely 2.5μg / mL C16-SW affinity lipopeptide experimental group, 5μg / mL C16-SW affinity lipopeptide experimental group, 10μg / mL C16-SW affinity lipopeptide experimental group, 20μg / mL C16-SW affinity lipopeptide experimental group and control group.

[0110] 2.5μg / mL C16-SW affinity lipopeptide experimental group: 1ml of 5μg / mL C16-SW affinity lipopeptide dilution was added to 1ml RTG-2 cell culture medium to obtain 2.5μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium. The experiment was repeated 5 times.

[0111] 5μg / mL C16-SW affinity lipopeptide experimental group: 1 ml of 10μg / mL C16-SW affinity lipopeptide diluent was added to 1 ml of RTG-2 cell culture medium to obtain 5μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium. The experiment was repeated 5 times.

[0112] 10μg / mL C16-SW affinity lipopeptide experimental group: Add 1ml of 20μg / mL C16-SW affinity lipopeptide diluent to 1ml RTG-2 cell culture medium to obtain 10μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium. The experiment was repeated 5 times.

[0113] 20μg / mL C16-SW affinity lipopeptide experimental group: 0.002ml of C16-SW affinity lipopeptide stock solution was added to 2ml of RTG-2 cell culture medium to obtain 20μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium. The experiment was repeated 5 times.

[0114] HA control lipopeptide control group: 0.002 ml of HA control lipopeptide stock solution was added to 2 ml of RTG-2 cell culture medium to obtain HA control lipopeptide RTG-2 cell culture medium. The experiment was repeated 5 times.

[0115] Untreated control group: 0.002 ml DMSO was added to 2 ml RTG-2 cell culture medium to obtain untreated control RTG-2 cell culture medium. The experiment was repeated 5 times.

[0116] The above-mentioned 2.5 μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium, 5 μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium, 10 μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium, 15 μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium, 20 μg / mL C16-SW affinity lipopeptide RTG-2 cell culture medium, HA control lipopeptide RTG-2 cell culture medium and untreated control RTG-2 cell culture medium were cultured at 20°C and 5% CO2 for 24 h, and then the cell culture medium was replaced with 2 ml of the above-prepared 50TCID 50 The IHN virus solution was replaced with 2 ml of C medium 2 hours later. After further culture at 15°C and 5% CO2 for 24 hours, the expression of IHNV N gene, the titer of virus in the cell supernatant and the expression of Mx1 gene were detected.

[0117] The specific method is as follows:

[0118] Detection of IHNV N gene expression: The cells were scraped with a scraper, and total cell RNA was extracted using an RNA extraction kit (Axygen, catalog number AP-MN-MS-RNA-250). TM RT Master Mix Kit (Takara, Catalog No. RR036A) was used for reverse transcription reaction to obtain cDNA. Premix Ex Taq TM II (Tli RNase H Plus) kit instructions (Takara, catalog number RR820A), using Applied Biosystems 7500 for fluorescence quantitative PCR reaction, 20μL reaction system is 10μL Premix Ex Taq TM II, 0.8μL upstream primer (10μM), 0.8μL downstream primer (10μM), 0.4μL ROX Reference Dye II (50×), 2μL cDNA template and 6μL sterile deionized water. The reaction conditions were 95℃ 30sec, then 95℃ 5sec, 60℃ 34sec, for a total of 40 cycles, and finally a melting curve was drawn. The internal reference selected the β-actin gene (primers were GCCGGCCGCGACCTCACAGACTAC and CGGCCGTGGTGGTGAAGCTGTAAC), the IHNV N gene detection primers were TGTGCATGAAGTCAGTGGTGG and CCTGCTCATCATGACACCGTA, and 2 -ΔΔCTThe relative changes of IHNV N gene in the experimental group were determined by the method compared with the untreated control group. Figure 5 Middle A( Figure 5 In figure A, 20 μg / mL, 10 μg / mL, 5 μg / mL and 2.5 μg / mL represent 20 μg / mL C16-SW affinity lipopeptide experimental group, 10 μg / mL C16-SW affinity lipopeptide experimental group, 5 μg / mL C16-SW affinity lipopeptide experimental group and 2.5 μg / mL C16-SW affinity lipopeptide experimental group, respectively; HA control lipopeptide is HA control lipopeptide control group, and untreated control is untreated control group). As shown in figure A, the expression level of IHNV N gene in the 20 μg / mL C16-SW affinity lipopeptide experimental group was significantly reduced compared with the HA control lipopeptide control group and the untreated control group, which was 0.35 times lower than that of the HA control lipopeptide group and 0.53 times lower than that of the untreated control group. Figure 5 2.5 μg / mL (C16-SW affinity lipopeptide 2.5 μg / mL) was the 2.5 μg / mL C16-SW affinity lipopeptide experimental group, 5 μg / mL was the 5 μg / mL C16-SW affinity lipopeptide experimental group, 10 μg / mL was the 10 μg / mL C16-SW affinity lipopeptide experimental group, 20 μg / mL was the 20 μg / mL C16-SW affinity lipopeptide experimental group, HA control lipopeptide was the HA control lipopeptide control group, and the untreated control was the untreated control group.

[0119] Detection of IHNV virus titer in cell culture supernatant: Use a pipette to aspirate all the cell culture supernatants of the 20 μg / mL C16-SW affinity lipopeptide experimental group, HA control lipopeptide control group and untreated control group, add 100 μL of the supernatant of the cells to be tested at a 10-fold dilution to a 96-well cell culture plate where RTG-2 cells have grown a monolayer, set up 8 replicate wells for each dilution, place in a CO2 incubator, and culture at 15°C. At the same time, set up a negative control group without adding virus, observe and record the cell pathological changes under a microscope every day, count the number of wells with cell pathological changes, and calculate TCID using the Reed-Muench method. 50 .

[0120] The results are as follows Figure 5 As shown in Figure B (20 μg / mL C16-SW affinity lipopeptide is the 20 μg / mL C16-SW affinity lipopeptide experimental group, HA control lipopeptide is the HA control lipopeptide control group, and the untreated control is the untreated control group), compared with the untreated control group, the virus titer in the HA control lipopeptide group did not change significantly, while the IHN virus titer in the 20 μg / mL C16-SW affinity lipopeptide experimental group was significantly reduced, with a reduction of 0.25 times.

[0121] Detection of the expression of the Mx1 gene: The cells were picked up with a scraper, and total cell RNA was extracted using an RNA extraction kit (Axygen, catalog number AP-MN-MS-RNA-250). TM RT Master Mix Kit (Takara, Catalog No. RR036A) was used for reverse transcription reaction to obtain cDNA. Premix Ex Taq TM II (Tli RNase H Plus) kit instructions (Takara, catalog number RR820A), using Applied Biosystems 7500 for fluorescence quantitative PCR reaction, 20μL reaction system is 10μL Premix Ex Taq TM II, 0.8μL upstream primer (10μM), 0.8μL downstream primer (10μM), 0.4μL ROX Reference Dye II (50×), 2μL cDNA template and 6μL sterile deionized water. The reaction conditions were 95℃ 30sec, then 95℃ 5sec, 60℃ 34sec, for a total of 40 cycles, and finally a melting curve was drawn. The internal reference selected the β-actin gene (primers were GCCGGCCGCGACCTCACAGACTAC and CGGCCGTGGTGGTGAAGCTGTAAC). The detection primers for the Mx1 gene were AGCGTCTGGCTGATCAGATT and AGCTGCTCGATGTTGTCCTT. 2 -ΔΔCT The relative changes of Mx1 gene in the experimental group were determined by the method compared with the untreated control group.

[0122] The results are as follows Figure 5 Middle C( Figure 5 In C, 20μg / mL, 10μg / mL, 5μg / mL and 2.5μg / mL represent 20μg / mL C16-SW affinity lipopeptide experimental group, 10μg / mL C16-SW affinity lipopeptide experimental group, 5μg / mL C16-SW affinity lipopeptide experimental group and 2.5μg / mL C16-SW affinity lipopeptide experimental group, respectively; HA control lipopeptide is HA control lipopeptide control group, and untreated control is untreated control group). As shown in Figure 2, compared with the untreated control group, there was no significant difference in the expression of Mx1 gene in the HA control lipopeptide group, while the 20μg / mL C16-SW affinity lipopeptide experimental group, 10μg / mL C16-SW affinity lipopeptide experimental group, 5μg / mL C16-SW affinity lipopeptide experimental group, and 2.5μg / mL The C16-SW affinity lipopeptide experimental groups could significantly enhance the expression of Mx1 gene, with the enhancement times being 1.28 times, 2.19 times, 1.46 times and 1.42 times respectively.

[0123] The results showed that C16-SW affinity lipopeptide could significantly inhibit the replication of viral genes at a concentration of 20 μg / mL ( Figure 5 A) and virus release ( Figure 5 B), but only slightly increased the expression of interferon effector protein Mx1, without causing excessive interferon response ( Figure 5 Middle C).

[0124] In order to further determine the function of SW polypeptide and expand its application methods. Based on the pEGFP-N1 vector (product of Miaoling Biotechnology Co., Ltd., P0133), the gene sequence encoding the SW polypeptide sequence 5'-GCCACCATGAGCTGGTGGTTTCCTCAGTGGATGGCCCAGTACCCTGGCGGCAGC-3' (sequence 7) was inserted into the pEGFP-N1 vector with HindIII and BamHI restriction sites, so that the gene sequence encoding the SW polypeptide sequence can be correctly expressed, and the recombinant eukaryotic expression plasmid PEGFP-SW (abbreviated as SW) encoding the affinity peptide was constructed.

[0125] RTG-2 cells grown to about 60%: RTG-2 cells in the logarithmic growth phase were plated at 2×10 5 The amount of cells was added to a 6-well plate, and cultured overnight at 20°C under 5% CO2 to obtain a 6-well plate of RTG-2 cells that had grown to about 60%.

[0126] The eukaryotic expression plasmid PEGFP-SW is a recombinant vector obtained by replacing the fragment between the restriction endonuclease HindIII and BamHI recognition sites in the pEGFP-N1 vector with 5'-GCCACCATGAGCTGGTGGTTTCCTCAGTGGATGGCCCAGTACCCTGGCGGCAGC-3', while keeping other sites of the pEGFP-N1 vector unchanged, and it is named eukaryotic expression plasmid PEGFP-SW.

[0127] The eukaryotic expression plasmid PEGFP-SW was transfected into 6-well plates of RTG-2 cells grown to about 60%, with a dose gradient of 5 μg of eukaryotic expression plasmid PEGFP-SW, 2 μg of eukaryotic expression plasmid PEGFP-SW, 1 μg of eukaryotic expression plasmid PEGFP-SW and 1 μg of empty vector plasmid (pEGFP-N1 vector) / well. The empty vector plasmid (pEGFP-N1 vector) was used as the empty vector transfection control in the experiment. Each experiment was repeated 3 times. The specific operation was as follows: referring to the instruction manual of Lipofectamine 3000 (product of Thermo Fisher Scientific, L3000008), two sterile EP tubes were prepared, and 125 μl of Opti-MEM culture medium (product of Thermo Fisher Scientific, 11058021) and 5 μl of Lipofectamine were added to tube 1. 3000 transfection reagent, add 125μl Opti-MEM medium, the plasmid to be transfected and the corresponding dose of P3000 reagent (add 2μl for every 1μg plasmid) (reagent in the #L3000008 kit) to tube 2, add the reagent in tube 2 dropwise to tube 1, mix well and perform transfection at room temperature. 24h after transfection, replace the cell culture medium with 2ml of the above-prepared 50TCID 50 The IHN virus solution was replaced with 2 ml of C medium after 2 h and culture was continued. The cell supernatant titer and the IHNV N gene expression level in the cells were detected after 24 h (the specific steps are the same as the above-mentioned "IHNV virus titer detection" step and "IHNV N gene expression level detection" step).

[0128] The results showed that compared with the control group, SW plasmid transfection significantly reduced the expression of viral genes, and the 5, 2, and 1 μg SW plasmid transfection groups decreased by 0.49, 0.54, and 0.57 times, respectively ( Figure 6 In A, the ordinate is the relative expression of IHNV genes. The 5 μg SW plasmid transfection, 2 μg SW plasmid transfection, 1 μg SW plasmid transfection and empty vector transfection controls correspond to the above 5 μg eukaryotic expression plasmid PEGFP-SW, 2 μg eukaryotic expression plasmid PEGFP-SW, 1 μg eukaryotic expression plasmid PEGFP-SW and 1 μg empty vector plasmid); SW plasmid transfection significantly reduced the virus titer, and the 5, 2, and 1 μg SW plasmid transfection groups all decreased by 0.02 times ( Figure 6In middle B, the ordinate is the IHNV titer, and the 5 μg SW plasmid transfection, 2 μg SW plasmid transfection, 1 μg SW plasmid transfection and empty vector transfection controls correspond to the above 5 μg eukaryotic expression plasmid PEGFP-SW, 2 μg eukaryotic expression plasmid PEGFP-SW, 1 μg eukaryotic expression plasmid PEGFP-SW and 1 μg empty vector plasmid, respectively. This shows that the plasmid transfected cells encoding the SW polypeptide sequence can still play a significant anti-IHNV effect.

[0129] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. A polypeptide or a pharmaceutically acceptable salt thereof, It is characterized in that The amino acid sequence of the polypeptide is sequence 1, sequence 3, sequence 2 or sequence 4 in the sequence list.

2. Derivatives of polypeptides, It is characterized in that The derivative is a compound obtained by subjecting the polypeptide according to claim 1 to at least one of the following modifications: A1) a compound obtained by connecting an amino terminal protecting group to the amino terminal of the polypeptide and / or connecting a carboxyl terminal protecting group to the carboxyl terminal of the polypeptide; A2) a polypeptide capable of specifically binding to rainbow trout SOCS-1 and resisting IHN virus obtained by adding amino acid residues to the amino terminus and / or carboxyl terminus of the polypeptide; A3) A polypeptide capable of specifically binding to rainbow trout SOCS-1 and resisting IHN virus is obtained by connecting fatty acids to the amino terminus and / or carboxyl terminus of the polypeptide.

3. Compounds, It is characterized in that The derivative is a compound of formula (I): F1-SWWFPQWMAQYP-X1-X2-F2 (Formula I), wherein F1 is a fatty acid, X1 represents GGS or does not exist, X2 represents YPYDVPDYA or does not exist, and F2 is a carboxyl terminal protecting group.

4. The compound according to claim 3, It is characterized in that The carboxyl terminal protecting group is an amino group.

5. The compound according to claim 3, It is characterized in that The fatty acid is palmitic acid.

6. Use of the polypeptide according to claim 1 or a pharmaceutically acceptable salt thereof, or a derivative of the polypeptide according to claim 2, or a compound according to any one of claims 3 to 5 in the preparation of a drug for preventing and / or treating and / or assisting in the treatment of infectious hematopoietic necrosis.

7. Use of the polypeptide according to claim 1 or a pharmaceutically acceptable salt thereof, or a derivative of the polypeptide according to claim 2, or a compound according to any one of claims 3 to 5 in the preparation of a drug for preventing and / or treating and / or assisting in the treatment of diseases caused by infectious hematopoietic necrosis virus.

8. Use of the polypeptide or pharmaceutically acceptable salt thereof according to claim 1, the polypeptide derivative according to claim 2, or the compound according to any one of claims 3 to 5 in the preparation of an anti-IHN virus drug.

9. Anti-IHN virus drugs, It is characterized in that The composition comprises the polypeptide according to claim 1 or a pharmaceutically acceptable salt thereof, or a derivative of the polypeptide according to claim 2, or a compound according to claim 3.

10. A method for preparing an anti-IHN virus drug, It is characterized in that The method comprises using the polypeptide or pharmaceutically acceptable salt thereof according to claim 1 or the polypeptide derivative according to claim 2 or the compound according to any one of claims 3 to 5 as a component of the drug to obtain an anti-IHN virus drug.

Citation Information

Patent Citations

  • Processing method of recombinant adenovirus vaccine for infectious hematopoietic necrosis and infectious pancreatic necrosis of salmonidae fishes

    CN115887638A

  • Bioreceptor molecules, the use of bioreceptor molecules, sensors containing electrodes modified with the said bioreceptor molecules and the detection method of SARS-cov-2 virus

    US20220365085A1

  • Bioreceptor molecules, the use of bioreceptor molecules, sensors containing electrodes modified by the said bioreceptor molecules, and method of detecting bacteria and viruses

    WO2021048750A1